Liu Tianze, Gan Hairun, He Simeng, Deng Jia, Hu Xinyan, Li Luting, Cai Li, He Jianzhong, Long Haoyu, Cai Jianxun, Li Hanjie, Zhang Qianqian, Wang Lijie, Chen Fangbin, Chen Yuming, Zhang Haopei, Li Jian, Yang Lukun, Liu Ye, Yang Jian-Hua, Kuang Dong-Ming, Pang Pengfei, He Huanhuan, Shan Hong
Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, P.R. China.
The Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, P.R. China.
Cancer Res. 2022 Sep 2;82(17):3074-3087. doi: 10.1158/0008-5472.CAN-21-3748.
Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies. Elucidating the underlying mechanisms of this disease could provide new therapeutic strategies for treating HCC. Here, we identified a novel role of DEAD-box helicase 24 (DDX24), a member of the DEAD-box protein family, in promoting HCC progression. DDX24 levels were significantly elevated in HCC tissues and were associated with poor prognosis of HCC. Overexpression of DDX24 promoted HCC migration and proliferation in vitro and in vivo, whereas suppression of DDX24 inhibited both functions. Mechanistically, DDX24 bound the mRNA618-624nt of laminin subunit beta 1 (LAMB1) and increased its stability in a manner dependent upon the interaction between nucleolin and the C-terminal region of DDX24. Moreover, regulatory factor X8 (RFX8) was identified as a DDX24 promoter-binding protein that transcriptionally upregulated DDX24 expression. Collectively, these findings demonstrate that the RFX8/DDX24/LAMB1 axis promotes HCC progression, providing potential therapeutic targets for HCC.
The identification of a tumor-promoting role of DDX24 and the elucidation of the underlying regulatory mechanism provide potential prognostic indicators and therapeutic approaches to help improve the outcome of patients with hepatocellular carcinoma.
肝细胞癌(HCC)是最具侵袭性的恶性肿瘤之一。阐明这种疾病的潜在机制可为治疗HCC提供新的治疗策略。在此,我们确定了DEAD盒解旋酶24(DDX24)(DEAD盒蛋白家族成员)在促进HCC进展中的新作用。DDX24水平在HCC组织中显著升高,且与HCC的不良预后相关。DDX24的过表达在体外和体内均促进HCC迁移和增殖,而抑制DDX24则抑制这两种功能。机制上,DDX24结合层粘连蛋白β1(LAMB1)的mRNA618 - 624nt,并以依赖于核仁素与DDX24 C末端区域相互作用的方式增加其稳定性。此外,调节因子X8(RFX8)被鉴定为DDX24启动子结合蛋白,其转录上调DDX24表达。总体而言,这些发现表明RFX8/DDX24/LAMB1轴促进HCC进展,为HCC提供了潜在的治疗靶点。
DDX24促肿瘤作用的鉴定及潜在调控机制的阐明提供了潜在的预后指标和治疗方法,有助于改善肝细胞癌患者的预后。